Hodgkins Lymphoma Treatment

PUBLISHED: August 14, 2024

PAGES: 127 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Global Hodgkins Lymphoma Treatment Market to Reach US$1.9 Billion by 2030

The global market for Hodgkins Lymphoma Treatment estimated at US$1.1 Billion in the year 2023, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 8.8% over the analysis period 2023-2030. Radiotherapy, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$1.0 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$280.5 Million While China is Forecast to Grow at 8.4% CAGR

The Hodgkins Lymphoma Treatment market in the U.S. is estimated at US$280.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$303.8 Million by the year 2030 trailing a CAGR of 8.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.2% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.9% CAGR.

Key Trends and Drivers

Hodgkin's lymphoma, a type of lymphatic cancer, is characterized by the presence of Reed-Sternberg cells and typically presents with symptoms like swollen lymph nodes, fever, night sweats, and weight loss. Treatment for Hodgkin's lymphoma has evolved significantly, with high cure rates, especially when diagnosed early. The standard treatment regimen includes a combination of chemotherapy and radiation therapy, which has been very effective in achieving remission in a majority of cases. More recently, the introduction of targeted therapies such as the CD30-directed monoclonal antibody, brentuximab vedotin, has provided an alternative for patients who relapse or do not respond to initial treatment. These advancements have significantly improved the prognosis for patients, reducing the long-term complications associated with traditional therapies.

As research progresses, there is a growing emphasis on minimizing treatment-related side effects and tailoring therapy regimens to reduce the risk of long-term toxicity while maintaining high cure rates. This includes the use of PET scans to guide the extent and duration of treatment, allowing some patients to avoid the risks associated with prolonged exposure to chemotherapy and radiation. Clinical trials continue to explore the efficacy of combining newer agents with standard therapies to enhance outcomes and decrease the likelihood of relapse. For example, checkpoint inhibitors that help the immune system recognize and destroy cancer cells are being tested in Hodgkin's lymphoma with promising results.

The growth in the Hodgkin's lymphoma treatment market is driven by several factors, including advances in diagnostic techniques that allow for earlier and more accurate detection of the disease, improving patient outcomes. Increased investment in research and development of new therapies, particularly in the realm of immunotherapy and targeted treatments, is rapidly transforming the therapeutic landscape. Additionally, the rise in patient awareness and advocacy ensures that more patients seek and receive timely, appropriate treatment. Global health initiatives focusing on cancer screening and education also contribute to the increased detection and treatment rates. Regulatory support for fast-tracking promising new treatments accelerates their availability to patients, further stimulating market growth.

Select Competitors (Total 37 Featured) -

Actiza Pharmaceutical Pvt., Ltd.
Alkem Laboratories Limited
Biogen, Inc.
Bristol-Myers Squibb Company
Cipla Ltd.
F. Hoffmann-La Roche Ltd.
Fresenius Kabi USA
Incyte Corporation
Leadiant Biosciences, Inc.
LGM Pharma
Merck & Co., Inc.
Novartis International AG
Ono Pharmaceutical Co., Ltd.
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.;

Product Code: MCP26830

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Global Economic Update
- Hodgkins Lymphoma Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Advancements in Chemotherapy and Radiotherapy Techniques
- Development of Targeted Therapies and Monoclonal Antibodies
- Increasing Effectiveness of Personalized Treatment Plans
- Global Incidence of Hodgkin's Lymphoma and Epidemiological Trends
- Patient Quality of Life Considerations Driving Treatment Innovations
- Role of Combination Therapies in Treatment Protocols
- Advances in Diagnostic Technologies Enhancing Early Detection
- Healthcare Infrastructure Improvements and Their Impact on Availability
- The Economic Impact of Lifelong Treatment and Monitoring
- Advocacy and Support Groups Influencing Policy Changes
- Challenges in Managing Long-Term Survivorship and Side Effects
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Hodgkins Lymphoma Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 3: World Historic Review for Hodgkins Lymphoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 4: World 16-Year Perspective for Hodgkins Lymphoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Radiotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 6: World Historic Review for Radiotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 7: World 16-Year Perspective for Radiotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 13: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 15: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 16: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Hodgkins Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 17: USA Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 18: USA Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 19: USA 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
CANADA
- TABLE 20: Canada Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 21: Canada Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 22: Canada 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
JAPAN
- Hodgkins Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 23: Japan Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 24: Japan Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 25: Japan 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
CHINA
- Hodgkins Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 26: China Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 27: China Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 28: China 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
EUROPE
- Hodgkins Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 29: Europe Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 30: Europe Historic Review for Hodgkins Lymphoma Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 31: Europe 16-Year Perspective for Hodgkins Lymphoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
- TABLE 32: Europe Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 33: Europe Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 34: Europe 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
FRANCE
- Hodgkins Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 35: France Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 36: France Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 37: France 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
GERMANY
- Hodgkins Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 38: Germany Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 39: Germany Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 40: Germany 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
ITALY
- TABLE 41: Italy Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 42: Italy Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 43: Italy 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Hodgkins Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 44: UK Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 45: UK Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 46: UK 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
REST OF EUROPE
- TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 48: Rest of Europe Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 49: Rest of Europe 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Hodgkins Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 51: Asia-Pacific Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 52: Asia-Pacific 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
REST OF WORLD
- TABLE 53: Rest of World Recent Past, Current & Future Analysis for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 54: Rest of World Historic Review for Hodgkins Lymphoma Treatment by Therapy - Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 55: Rest of World 16-Year Perspective for Hodgkins Lymphoma Treatment by Therapy - Percentage Breakdown of Value Sales for Radiotherapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030